The comparative effectiveness of coronary artery bypass graft (CABG) surgery and percutaneous coronary intervention (PCI) for patients in whom both procedures are feasible remains poorly understood.
C
oronary artery bypass graft (CABG) surgery and catheter-based percutaneous coronary intervention (PCI), with or without coronary stents, are alternative approaches to mechanical coronary revascularization. These 2 coronary revascularization techniques are among the most common major medical procedures performed in North America and Europe: In 2005, 261 000 CABG procedures and 645 000 PCI procedures were performed in the United States alone (1) . However, the comparative effectiveness of CABG and PCI remains poorly understood for patients in whom both procedures are technically feasible and coronary revascularization is clinically indicated.
In patients with left main or triple-vessel coronary artery disease with reduced left ventricular function, CABG is generally preferred because randomized, controlled trials (RCTs) have shown that it improves survival compared with medical therapy (2, 3) . In patients with most forms of single-vessel disease, PCI is generally the preferred form of coronary revascularization (4) , in light of its lower clinical risk and the evidence that PCI reduces angina and myocardial ischemia in this subset of patients (5) . Most RCTs comparing CABG and PCI have been conducted in populations with coronary artery disease between these extremes, namely patients with single-vessel, proximal left anterior descending disease; most forms of double-vessel disease; or less extensive forms of triple-vessel disease.
We sought to evaluate the evidence from RCTs on the comparative effectiveness of PCI and CABG. We included trials using balloon angioplasty or coronary stents because quantitative reviews have shown no differences in mortality or myocardial infarction between these PCI techniques (6, 7) . We also included trials using standard or minimally invasive CABG or both procedures (8, 9) . We sought to document differences between PCI and CABG in survival, cardiovascular complications (such as stroke and myocardial infarction), and freedom from angina. Finally, we re-each outcome. We assessed the quality of included trials by using predefined criteria and graded their quality as A, B, or C by using methods described in detail elsewhere (10) . In brief, a grade of A indicates a high-quality trial that clearly described the population, setting, interventions, and comparison groups; randomly allocated patients to alternative treatments; had low dropout rates; and reported intention-to-treat analysis of outcomes. A grade of B indicates a randomized trial with incomplete information about methods that might mask important limitations. A grade of C indicates that the trial had evident flaws, such as improper randomization, that could introduce significant bias.
Data Synthesis and Analysis
We used random-effects models to compute weighted mean rates and SEs for each outcome. We computed summary risk differences and odds ratios between PCI and CABG and the 95% CI for each outcome of interest at annual intervals. Because the results did not differ materially when risk differences and odds ratios (10) were used and the low rate of several outcomes (for example, procedural mortality) made the risk difference a more stable outcome metric (11, 12) , we report here only the risk differences.
We assessed heterogeneity of effects by using chisquare and I 2 statistics (13) . When effects were heterogeneous (I 2 Ͼ 50%), we explored the effects of individual studies on summary effects by removing each study individually. We assessed the possibility of publication bias by visual inspection of funnel plots and calculated the number of missing studies required to change a statistically significant summary effect to not statistically significant (11) . We performed analyses by using Comprehensive Meta-Analysis software, version 2.0 (Biostat, Englewood, New Jersey).
Inclusion of Observational Studies
We also searched for observational data to evaluate the generalizability of the RCT results, as reported in detail elsewhere (10) . In brief, we included observational studies from clinical or administrative databases that included at least 1000 recipients of each revascularization procedure and provided sufficient information about the patient populations (such as demographic characteristics, preprocedure coronary anatomy, and comorbid conditions) and procedures performed (such as balloon angioplasty vs. baremetal stents vs. drug-eluting stents).
Role of the Funding Source
This project was supported by the Agency for Healthcare Research and Quality. Representatives of the funding agency reviewed and commented on the study protocol and drafts of the manuscript, but the authors had final responsibility for the design, conduct, analysis, and reporting of the study.
Context
The relative benefits and harms of coronary artery bypass graft surgery (CABG) versus percutaneous coronary intervention (PCI) are sometimes unclear.
Contribution
This systematic review of 23 randomized trials found that survival at 10 years was similar for CABG and PCI, even among diabetic patients. Procedural strokes and angina relief were more common after CABG (risk difference, 0.6% and about 5% to 8%, respectively), whereas repeated revascularization procedures were more common after PCI (risk difference, 24% at 1 year).
Caution
Only 1 small trial used drug-eluting stents. Few patients with extensive coronary disease or poor ventricular function were enrolled.
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RESULTS
We identified 1695 potentially relevant articles, of which 204 merited full-text review (Appendix Figure, available at www.annals.org). A total of 113 articles reporting on 23 unique RCTs met inclusion criteria (Table 1  [ 14 -126] ). These trials enrolled a total of 9963 patients, of whom 5019 were randomly assigned to PCI and 4944 to CABG. Most trials were conducted in Europe, the United Kingdom, or both locations; only 3 trials were performed in the United States. The early studies (patient entry from 1987 to 1993) used balloon angioplasty as the PCI technique, and the later studies (patient entry from 1994 to 2002) used stents as the PCI technique. Only 1 small trial of PCI versus CABG used drug-eluting stents (116) . Nine trials limited entry to patients with single-vessel disease of the proximal left anterior descending artery, whereas the remaining 14 trials enrolled patients with multivessel disease, either predominantly (3 trials) or exclusively (11 trials).
The quality of 21 trials was graded as A, and 1 trial (117) was graded as B. One trial (116) was graded as C because randomization may not have been properly executed (details are available elsewhere [10] ). We performed sensitivity analyses by removing these studies from the analysis, and our summary results did not change statistically significantly.
The average age of the trial participants was 61 years, 27% were women, and most were of European ancestry. Roughly 20% had diabetes, half had hypertension, and half had hyperlipidemia. Whereas approximately 40% of patients had a previous myocardial infarction, few had heart failure or poor left ventricular function. Among studies that enrolled patients with multivessel coronary disease, most had double-vessel rather than triple-vessel disease.
Revascularization procedures were performed by using standard methods for the time the trial was conducted ( Table 1) . Among patients with multivessel disease, more grafts were placed during CABG than vessels were dilated during PCI. Among patients assigned to PCI, stents were commonly used in the recent studies, but in the earlier trials, balloon angioplasty was standard. Among patients assigned to CABG, arterial grafting with the left internal mammary artery was frequently done, especially in more recent trials. Some studies used minimally invasive, direct coronary artery bypass and off-pump operations to perform CABG in patients with single-vessel left anterior descending disease ( Table 1) .
Short-Term and Procedural Outcomes
Survival (within 30 days of the procedure) was high for both procedures: 98.9% for PCI and 98.2% for CABG. When data from all trials were combined, the survival difference between PCI and CABG was small and not statistically significant (0.2% [95% CI, Ϫ0.3% to 0.6%]) (Figure 1) . These results were unchanged after exclusion of AWESOME (Angina With Extremely Serious Operative Mortality Evaluation) (28) and the Myoprotect I (104) trial, which enrolled patients who were more acutely ill.
The rate of procedural stroke (reported in 15 randomized trials) was higher after CABG (1.2%) than after PCI (0.6%) (Figure 1) . The difference between PCI and CABG in procedural stroke was 0.6% (CI, 0.2% to 1%) (P ϭ 0.002). Procedural myocardial infarction was not assessed in a consistent manner across trials of PCI and CABG. The pooled PCI-CABG difference in freedom from procedural myocardial infarction was small and not statistically significant (0.1% [CI, Ϫ1.0% to 1.2%]).
Long-Term Outcomes Survival
Follow-up in the RCTs ranged from 6 months to 13 years. Overall survival across all randomized trials was similar between CABG and PCI at 1 year (96.4% vs. 96.5%) and 5 years (90.7% vs. 89.7%) of follow-up. The absolute survival difference between PCI and CABG at each time point was less than 1%. The 4 trials that reported longer follow-up (62, 80, 88, 110) showed no consistent change in the PCI-CABG survival difference after 5 years. We found no evidence of probable publication bias.
The comparative survival benefit did not differ significantly when randomized trials were subdivided into those enrolling patients with single-vessel proximal left anterior descending disease and those enrolling patients with multivessel disease (Figure 2) . Among trials of multivessel disease, PCI and CABG results did not differ substantially for trials using balloon angioplasty versus trials using stents (Figure 3) .
Other Long-Term Outcomes
Angina relief was more common after CABG than after PCI at 1, 3, and 5 years after the procedure. At 1 year, the proportion of patients without angina was 75% in PCI-assigned patients and 84% in CABG-assigned patients; at 5 years, this value increased to 79% in PCIassigned patients but remained 84% percent in CABGassigned patients. The PCI-CABG risk difference ranged from 5% to 8% between 1 and 5 years after the procedure (P Ͻ 0.001).
A greater proportion of patients who had CABG was without repeated coronary revascularization (96.2% at 1 year and 90.2% at 5 years) compared with patients who had PCI (73.5% at 1 year and 53.9% at 5 years for balloon angioplasty trials and 59.9% at 5 years for stent trials). Patients who received PCI required 24% more repeated procedures than CABG recipients at 1 year (P Ͻ 0.001) and 33% more repeated procedures at 5 years (P Ͻ 0.001). Although the trials consistently favored CABG, the results were statistically heterogeneous (I 2 ϭ 93 at 1 year, and I 2 ϭ 78 at 5 years). This difference between PCI and CABG was greater in trials that used balloon angioplasty (Ϫ37% [CI, Ϫ42% to Ϫ31%]) than in trials that used coronary stents (Ϫ27% [CI, Ϫ39% to Ϫ16%]), although patients undergoing PCI with stents still required more repeated procedures than did patients undergoing CABG.
Ten studies reported myocardial infarction rates in long-term follow-up, which increased among all patients between 1 and 5 years, but at a somewhat higher rate for PCI recipients. At 5 years, the mean (ϮSE) rate of myocardial infarction was 11.9% Ϯ 3.0% for PCI recipients and 10.9% Ϯ 2.6% for CABG recipients. The summary differences in myocardial infarction between PCI and CABG were less than 1%.
Comparative Effectiveness
Most trials did not report outcomes in subgroups, and even fewer performed formal statistical interaction tests to gauge whether outcomes varied in a statistically significant manner by clinical characteristics. Outcomes were reported by 5 or more trials only for the subgroups defined by diabetes, age, sex, smoking, and number of diseased vessels. Evidence was insufficient to evaluate whether hypertension, race, obesity, renal dysfunction, peripheral vascular disease, previous coronary revascularization procedures, clinical presentation, or left ventricular function affected the comparative outcomes of PCI and CABG, because each of these characteristics was reported in only 1 to 3 trials (10).
Outcomes by age were examined by BARI (Bypass Angioplasty Revascularization Intervention) (57), AWE-SOME (31), and a pooled analysis of 4 (127) . Overall, older patients had more procedural complications, especially stroke. Long-term survival after PCI or CABG did not differ significantly among patients older than 65 years of age compared with younger patients, but very few patients older than 75 years of age were enrolled. Six trials reported on comparative survival among patients with diabetes (Figure 4) . Whereas BARI reported a survival advantage for CABG among patients with diabetes (37, 64), the other 5 trials did not. At 5 years, the mean (ϮSE) summary survival rate was 79.2% Ϯ 5.8% for PCI recipients and 82.2% Ϯ 5.6% for CABG recipients. When we combined all trials, survival in patients with diabetes at 5 years was higher for CABG by only 0.2%, but the confidence bounds of this estimate were wide (Ϫ8.8% to 8.3%).
Outcomes in patients with double-vessel disease were compared with those in patients with triple-vessel disease in BARI (40), EAST (Emory Angioplasty versus Surgery Trial) (80), ERACI II (86) , and the pooled analysis of the stent trials (127) . In each instance, the survival advantage of CABG was greater for triple-vessel disease than for doublevessel disease, but the difference between CABG and PCI was not statistically significant in any trial.
No sex-based difference in survival (55) or cardiovascular events (127) was observed between PCI and CABG. Similarly, cigarette smoking was not associated with a difference in outcomes between the interventions (38, 62, 127).
Mortality Rates in Clinical Registries
Five major clinical registries (128 -132) included more than 1000 patients who received PCI and 1000 patients who received CABG, reported long-term survival patterns, and used multivariable statistical methods to adjust for clinical differences in patients selected for PCI and CABG ( Table 2) . These registries reported striking differences in the patients selected for these 2 procedures: Most patients with single-vessel disease received PCI, and most patients with triple-vessel disease received CABG. Across the spectrum of disease severity, the CABG-PCI hazard ratio for mortality ranged from 0.48 to 0.86 favoring CABG (128, 129) . The CABG-PCI hazard ratio was affected by the extent of coronary disease. In the Duke University Medical Center registry (130) , the CABG-PCI hazard ratio varied from 2.1 among patients with the least severe disease to 0.45 in patients with the most severe disease. Similar variations in the hazard ratio according to severity of disease were reported by various investigators using the Alberta, Canada (131); northern New England (129); and New York State (132) registries. In the patients with intermediate extent of disease who were most similar to patients enrolled in randomized trials, the studies based on data from clinical registries reported CABG-PCI hazard ratios close to 1.0.
DISCUSSION
Our review of 23 randomized trials found that longterm survival did not statistically significantly differ be- 
Overall
The size of each box is proportional to the sample size of the trial. Bars represent 95% CIs. The I 2 statistic was Ͻ1 for both procedural survival and procedural stroke risk. AMIST ϭ Angioplasty versus Minimally Invasive Surgery Trial; ARTS ϭ Arterial Revascularization Therapies Study; AWESOME ϭ Angina with Extremely Serious Operative Mortality Evaluation; BARI ϭ Bypass Angioplasty Revascularization Investigation; CABG ϭ coronary artery bypass grafting; CABRI ϭ Coronary Angioplasty versus Bypass Revascularization Investigation; EAST ϭ Emory Angioplasty versus Surgery Trial; ERACI ϭ Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease; GABI ϭ German Angioplasty Bypass Surgery Investigation; MASS ϭ Medicine, Angioplasty, or Surgery Study; PCI ϭ percutaneous coronary intervention; RITA ϭ Randomized Intervention Treatment of Angina; SIMA ϭ Stenting versus Internal Mammary Artery Study; SoS ϭ Stent or Surgery. *Survival data were abstracted from Kaplan-Meier curves. tween PCI and CABG among patients in whom coronary revascularization is clinically indicated and in whom both procedures are technically feasible. Despite this similarity in long-term survival, several distinct differences between these alternative coronary revascularization procedures may affect the choice of procedure. The short-term risk for stroke was higher with CABG than with PCI, yet the frequency of angina was lower after CABG than after PCI over 5 years. Patients who received CABG also underwent fewer repeated revascularization procedures than did patients who received PCI, even when coronary stents were used.
Coronary revascularization methods continue to be refined, so that evaluation of the outcomes of PCI and CABG remains a moving target. Percutaneous coronary intervention has evolved from its initial reliance on balloon angioplasty techniques to use of bare-metal stents and, more recently, drug-eluting stents. Although these refinements in PCI technique have progressively reduced restenosis and the need for repeated coronary revascularization procedures, they have not reduced the rate of mortality or myocardial infarction after PCI (6, 7). Consequently, the earlier trials of PCI versus CABG continue to provide pertinent evidence about the "hard outcomes" of greatest importance after coronary revascularization. Techniques Randomized trials enroll patients who meet strict inclusion and exclusion criteria and are conducted in centers chosen to have excellent clinical results and high procedure volumes. The perennial question about all randomized trials is whether their results can be generalized to less selected patient populations and practice settings. The randomized trials of PCI and CABG enrolled few patients who were older than 75 years of age; had poor left ventricular function, heart failure, or ongoing clinical instability; or had undergone previous CABG or PCI procedures. The results of the randomized trials, and our synthesis of those results, do not necessarily apply to these and other populations that were not well represented. The greatest difference between patients enrolled in the clinical trials and those in typical practice was the requirement that both PCI and CABG be technically feasible and provide adequate revascularization in all randomly assigned patients. In large clinical registries, patients selected for PCI differ in important ways from patients chosen for 
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The size of each box is proportional to the sample size of the trial. Bars represent 95% CIs. The I 2 statistic for 5-year survival was 10 among MVD trials using balloon angioplasty and Ͻ1.0 among trials using stents. ARTS ϭ Arterial Revascularization Therapies Study; AWESOME ϭ Angina with Extremely Serious Operative Mortality Evaluation; BARI ϭ Bypass Angioplasty Revascularization Investigation; BMS ϭ bare-metal stent; CABG ϭ coronary artery bypass grafting; EAST ϭ Emory Angioplasty versus Surgery Trial; ERACI ϭ Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease; GABI ϭ German Angioplasty Bypass Surgery Investigation; MASS ϭ Medicine, Angioplasty, or Surgery Study; PCI ϭ percutaneous coronary intervention; RITA ϭ Randomized Intervention Treatment of Angina. *Survival data were abstracted from Kaplan-Meier curves. 
Overall
The size of each box is proportional to the sample size of the trial. Bars represent 95% CIs. The I 2 statistic was 40. All studies that reported comparative effectiveness data for patients with diabetes were included in this analysis, not just studies that reported comparative outcomes for patients with and without diabetes. Hazard ratios from the German Angioplasty Bypass Surgery Investigation for death after PCI or CABG were reported to not differ between patients with or without diabetes; however, these data were not shown. AWESOME ϭ Angina with Extremely Serious Operative Mortality Evaluation; BARI ϭ Bypass Angioplasty Revascularization Investigation; CABG ϭ coronary artery bypass grafting; EAST ϭ Emory Angioplasty versus Surgery Trial; ERACI ϭ Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease; MASS ϭ Medicine, Angioplasty, or Surgery Study; PCI ϭ percutaneous coronary intervention; RITA ϭ Randomized Intervention Treatment of Angina.
CABG: Most patients treated with PCI have single-vessel coronary disease, whereas most patients treated with CABG have triple-vessel or left main coronary disease, and many have reduced left ventricular function (136, 137). The patients enrolled in clinical trials generally had an extent of coronary disease that fell between these 2 extremes, and the results of randomized trials may not apply to patients with less extensive or more extensive coronary disease.
Our finding of similar long-term survival after randomization to PCI or CABG differs from the findings of studies based on several large clinical registries, which have reported improved survival after CABG ( Table 2) . These large clinical registry studies were observational, nonrandomized comparisons, however, and are inherently less reliable than randomized trials because strong selection biases may be present that even sophisticated statistical adjustment techniques cannot remove. Clinical registry studies have shown that the extent and severity of coronary disease, which are the major factors determining selection for PCI versus CABG, strongly affect relative survival after PCI or CABG (129 -131) . In an analysis of information from the Duke University Medical Center database, survival after PCI and CABG was equivalent among patients who had an intermediate extent of coronary disease, similar to that of patients eligible for randomization in trials of PCI versus CABG (130) . These observations suggest that the seemingly disparate results of randomized trials and clinical registries can be reconciled by taking into account that the overall outcomes in clinical registries are heavily weighted by the larger number of events in the higher-risk patients with the most extensive disease-who seem to have better outcomes after CABG than after PCI-whereas overall outcomes in the randomized trials were assessed in intermediate-risk patients-in whom CABG and PCI outcomes were also similar in clinical registries (130) .
The potential for variation in the comparative effectiveness of treatments according to patient characteristics is very important to clinical decision making. Large clinical trials now commonly report relative risk reductions in several subgroups of interest, as well as in the overall population, but statistically significant variations in subgroup outcomes are distinctly unusual. Significant variations in treatment effect are very difficult to demonstrate because statistical power is reduced by the smaller sample sizes in subgroups, and patient selection narrows the range of variation in key clinical variables, which may further reduce the power to detect subgroup effects on outcome.
Although the comparative effectiveness of PCI and CABG in patient subgroups was our particular focus (10), we found that outcomes in key clinical subgroups were reported too infrequently to permit drawing reliable conclusions about most clinical characteristics of interest. The most extensive evidence pertains to patients with diabetes and those with triple-vessel versus double-vessel disease.
The adverse prognostic effect of diabetes has been reported consistently in patients undergoing coronary revascularization procedures and may be due to more extensive coronary disease at the time of revascularization, more rapid progression of coronary atherosclerosis in follow-up, or both factors. The finding of BARI that CABG reduced mortality compared with PCI among patients with diabetes, but not among patients without diabetes (64), has resulted in much debate. Summary data from 7 randomized trials that reported outcomes in this subgroup (Figure 4) shows that the overall survival advantage of CABG over PCI in patients with diabetes was small (0.9%) and was not statistically significant, but with wide CIs. This result is consistent with reports from several clinical registries that comparative survival after PCI and CABG is similar in patients with diabetes (138 -140) . Our finding supports the conclusion that there is clinical equipoise on this question, and that the ongoing randomized trials comparing CABG and PCI in patients with diabetes (such as Four randomized trials reported a larger difference in survival between CABG and PCI in patients with triplevessel disease than in patients with double-vessel disease. Although this evidence is inconclusive, it is provocative in light of the strong and statistically significant effect of the extent of coronary disease on the relative hazard after PCI or CABG reported by the Duke database and other large clinical registries (129, 130, 133) . This hypothesis could be tested by pooling individual patient-level data from randomized trials of PCI and CABG conducted in patients with multivessel disease.
Our study has limitations. It is a quantitative overview and is necessarily limited to the analysis of aggregate data from published trials. Subgroup data were incompletely and inconsistently reported; our analysis of subgroup effects may therefore be subject to publication bias if subgroups were selected for publication based in part on the outcomes. Five-year outcomes from the SoS trial (119) have not yet been published and were not available for analysis. Most important, no results from large ongoing trials using drug-eluting stents have been published.
Our analysis has identified numerous gaps in evidence of the comparative effectiveness of PCI and CABG that are opportunities for future research. The paucity of published data of PCI and CABG outcomes according to patient characteristics suggests the value of a collaborative pooling of individual patient-level data from the randomized trials to enhance statistical power to identify subgroup effects and to reduce publication bias by including data from all trials. Clinical trials are also needed to assess whether the availability of drug-eluting stents has affected the comparative efficacy of PCI and CABG. These trials, which are under way, are particularly needed because pooled studies suggest no difference in survival and freedom from myocardial infarction between bare-metal stents and drug-eluting stents over the medium term. Recent safety concerns about drug-eluting stents emphasize the need for extended follow-up and trials large enough to detect clinically meaningful differences in outcomes. 
